Short Interest in Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Decreases By 70.6%

by · The Markets Daily

Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totaling 623 shares, a decline of 70.6% from the November 30th total of 2,121 shares. Based on an average trading volume of 13,663 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 13,663 shares, the short-interest ratio is presently 0.0 days.

Relief Therapeutics Price Performance

Shares of OTCMKTS:RLFTF traded down $0.10 during trading hours on Friday, hitting $2.95. The stock had a trading volume of 1,193 shares, compared to its average volume of 3,339. The stock’s fifty day simple moving average is $3.44 and its 200 day simple moving average is $3.32. Relief Therapeutics has a 1-year low of $1.40 and a 1-year high of $4.93.

About Relief Therapeutics

(Get Free Report)

Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.

The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.

Recommended Stories